Advertisement

Study of serum phosphohexose isomerase (PHI) levels in the management of head and neck malignancies

  • P. C. Verma
  • T. Ojha
  • D. Yadav
  • D. D. Hemani
Article
  • 26 Downloads

Abstract

The enzyme phosphohexose isomerase PHI was estimated in 43 patients of head and neck malignancy. The serum level of this enzyme was found to be raised in all the cancer patients. It was found that there were significantly higher levels of serum PHI in cases with metastatic lesions. The rise in PHI values was proportionate with the clinical stage of tumor. 29 Patients, out of 43 who had taken complete treatment weresubjected to post therapeutic PHI level estimations and the response to treatment was evaluated. Study showed that estimation of serum PHI levels have significant role in diagnosis of cancer, early detection of residual growth, recurrent growth and secondaries.

Keywords

Neck Cancer Serum Enzyme Neck Malignancy Cervical Metastasis Proliferative Growth 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bhatia, P.L., Singh, M.M. and Chakaravorty, M. (1979): Enzymatic study in diagnosis of head and neck cancer. Indian J. of Otolaryngology. 31: 76–79.Google Scholar
  2. 2.
    Bodansky, O. (1954): Serum phosphohexose Isomerase in cancer I: Method of determination and establishment of range and normal values. Cancer. 7:1191–1199.PubMedCrossRefGoogle Scholar
  3. 3.
    Bodansky, O. (1954): Serum hexose isomerase in cancer II, as an index of tumor growth in metastatic carcinoma of breast. Cancer 7:1200–1226.PubMedCrossRefGoogle Scholar
  4. 4.
    Goel, H., Kohli G.S. and Lai, H. (1986): Serum phosphohexose isomerase levels in patients with head and neck cancer. J. of Laryngology and Otology 100:581–585.Google Scholar
  5. 5.
    Priestman, T.J. (1977): Cancer chemotherapy, an introduction, Montedison Pharmaceuticals Ltd., Herts. U.S.A. p. 22.Google Scholar
  6. 6.
    Rao, Y.N., Chakravorty, M., and Khanna N.N. (1976): Serum phosphohexose isomerase in cancer. Indian J. of Cancer. 13: 361–366.Google Scholar
  7. 7.
    Schwartz, M.A., Walsh, S., West, N. and Zimmerman, H.J. (1962b). Serum enzymes in diseases X. Glycolytic and oxidative enzymes and transaminaes in patients with carcinoma of head, neck and oesophagus. Cancer. 15:927–930.PubMedCrossRefGoogle Scholar
  8. 8.
    Vaid, P., Sharma, D.C. and Shastri, K.D. (1974): a clinicobiochemical study of phosphohexose isomerase, aliesterase and sulfhydral group in 25 normal and 35 cancer sustpects. Indian J. of Cancer. 1:448–456.Google Scholar
  9. 9.
    Warburg, O. and Christian, W. (1943): Ganengsfermente in Blutdrumvon Tumor Ratten. Bio. Chem. Ztshr. 314:399–408.Google Scholar

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • P. C. Verma
    • 1
  • T. Ojha
    • 1
  • D. Yadav
    • 2
  • D. D. Hemani
    • 3
  1. 1.Deptt. of ENTJ.L.N. HospitalAjmer
  2. 2.ENTR.N.T. Medical College Hosp.Udaipur
  3. 3.Deptt. of ENTS.N. Medical CollegeJpdhpur

Personalised recommendations